Research programme: intranasal therapeutic agents - Cognition Life Science

Drug Profile

Research programme: intranasal therapeutic agents - Cognition Life Science

Latest Information Update: 18 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of South Florida
  • Developer Cognition Life Science; University of South Florida
  • Class Antidementias; Antiparkinsonians; Cannabinoids; Non-opioid analgesics
  • Mechanism of Action Cannabinoid receptor agonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Alzheimer's disease; Pain; Parkinson's disease; Sleep disorders

Most Recent Events

  • 13 Jan 2016 Cognition Life Science acquires proprietary formulations for the treatment of Neurodegenerative disorders, Sleep disorders, mental acuity and pain management from University of South Florida
  • 13 Jan 2016 Early research in Alzheimer's disease, Parkinson's disease, Sleep disorders and Pain in USA (Intranasal) before January 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top